Skip to content
OpenCapital
Get started

QuidelOrtho Corporation QDEL EV / sales

EV / sales at other companies

Abbott logo
AbbottABT
4.6×-1.0×
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
3.1×+0.1×
Danaher logo
DanaherDHR
6×-0.8×
Revvity logo
RevvityRVTY
4.4×-0.9×
Quest Diagnostics logo
Quest DiagnosticsDGX
2.4×0.0×
Opko Health logo
Opko HealthOPK
1.6×-0.1×

Other financials

Income statement

See full
Revenue$619.8M-10.5%
Gross profit$263.8M-23.2%
Operating income-$31.8M-198%
Net income-$91.8M-623%
EPS (diluted)-$1.35-611%

Balance sheet

See full
Cash & equivalents$140.4M+10.4%
Total debt$3.1B+0.3%
Total equity$1.9B-38.2%
Total assets$5.6B-12.9%

Cash flow

See full
Operating cash flow-$33.0M-150%
CapEx$34.0M-39.5%
Free cash flow-$67.0M-813%

Valuation

See full
Market cap$832.61M-51.4%
Enterprise value$3.8B-20.1%
P/S0.3×-0.3×

Profitability

See full
Gross margin45%-2.0pp
Operating margin-37%-46.2pp
Net margin-45.6%-75.7pp
FCF margin13.8%—

Returns & leverage

See full
Return on equity-49.9%-70.8pp
Debt / equity1.7×+0.6×
Current ratio1.4×+0.2×

Where this comes from

Calculated from QuidelOrtho Corporation’s reported figures.

enterprise value/total revenue=1.4×

Based on the most recent quarter.

The official record: QuidelOrtho Corporation’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about QuidelOrtho Corporation's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is QuidelOrtho Corporation's EV / sales?
QuidelOrtho Corporation (QDEL) reported EV / sales of 1.4× in Q1 2026.
How has QuidelOrtho Corporation's EV / sales changed year-over-year?
QuidelOrtho Corporation's EV / sales decreased by 18.3% year-over-year, from 1.8× to 1.4×.
What is the long-term trend for QuidelOrtho Corporation's EV / sales?
Over 4 years (2021 to 2025), QuidelOrtho Corporation's EV / sales has grown at a -5.4% compound annual growth rate (CAGR), from 2.1× to 1.7×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.